Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol

被引:53
作者
Pan, LP [1 ]
Wijnant, P [1 ]
De Vriendt, C [1 ]
Rosseel, MT [1 ]
Belpaire, FM [1 ]
机构
[1] State Univ Ghent, Sch Med, Heymans Inst Pharmacol, B-9000 Ghent, Belgium
关键词
cytochrome P450 isoenzymes; CYP3A4; haloperidol; human liver microsomes; in vitro metabolism;
D O I
10.1046/j.1365-2125.1997.t01-1-00629.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims The present study was carried out to identify the cytochrome P450 isoeneyme(s) involved in the N-dealkylation of haloperidol (HAL). Methods In vitro studies were performed using human liver microsomes and c-DNA-expressed human P450 isoforms. N-dealkylation of HAL was assessed by measuring the formation of 4-(4-chlorophenyl)-4-hydroxypiperidine (CPHP). Results There was a tenfold variation in the extent of CPHP formation amongst the nine human liver microsomal preparations. The CPHP formation rates as a function of substrate concentration, measured in three Lives, followed monophasic enzyme kinetics. K-m and V-max values ranged respectively from 50 to 78 mu M and from 180 to 412 pmol mg(-1) min CPHP formation rates in the nine liver preparations were significantly correlated with dextromethorphan N-demethylase activity (a marker of CYP3A4 activity), but not with the activity of dextromethorphan O-demethylase (CYP2D6), phenacetin O-deethylase (CYP1A2) or tolbutamide hydroxylase (CYP2C9). Ketoconazole, an inhibitor of CYP3A4, inhibited competitively CPHP formation (K-i=0.1 mu M), whereas sulphaphenazole (CYP2C9), furafylline (CYP1A2) and quinidine (CYP2D6) gave only little inhibition (IC50 > 100 mu M). CPHP formation was, moreover, enhanced by alpha-naphtoflavone, an effect common to CYP3A4 mediated reactions. Anti-CYP3A4 antibodies strongly inhibited CPHP formation, whereas no inhibition was observed in the presence of CYP2D6 antibodies. Among the recombinant human CYP isoforms tested, CYP3A4 exhibited the highest activity with respect to CPMP formation rate, with no detectable effect of other CYP isoforms (CYP1A2, CYP2D6 and CYP2C9). HAL inhibited dextromethorphan O-demethylase (CYP2D6) with IC50 values between 2.7 and 8.5 mu M, but not (IC50 > 100 mu M) dextromethorphan N-demethylase (CYP3A4), phenacetin O-deethylase (CYP1A2) or tolbutamide hydroxylase (CYP2C9). Conclusions These results strongly suggest that the N-dealkylation of HAL in human liver microsomal preparations is mediated by CYP3A4.
引用
收藏
页码:557 / 564
页数:8
相关论文
共 33 条
[1]   ANALYTICAL STUDY OF MICROSOMES AND ISOLATED SUBCELLULAR MEMBRANES FROM RAT-LIVER .2. PREPARATION AND COMPOSITION OF MICROSOMAL FRACTION [J].
AMARCOSTESEC, A ;
BEAUFAY, H ;
WIBO, M ;
THINESSE.D ;
FEYTMANS, E ;
ROBBI, M ;
BERTHET, J .
JOURNAL OF CELL BIOLOGY, 1974, 61 (01) :201-212
[2]   High performance liquid chromatography determination of dextromethorphan and its metabolites in urine using solid-phase extraction [J].
Bartoletti, RA ;
Belpaire, FM ;
Rosseel, MT .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1996, 14 (8-10) :1281-1286
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]   THE DETERMINATION OF ENZYME INHIBITOR CONSTANTS [J].
DIXON, M .
BIOCHEMICAL JOURNAL, 1953, 55 (01) :170-171
[5]   QUANTITATIVE-ANALYSIS OF 2 PYRIDINIUM METABOLITES OF HALOPERIDOL IN PATIENTS WITH SCHIZOPHRENIA [J].
EYLES, DW ;
MCLENNAN, HR ;
JONES, A ;
MCGRATH, JJ ;
STEDMAN, TJ ;
POND, SM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (05) :512-520
[6]   Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol [J].
Fang, J ;
Baker, GB ;
Silverstone, PH ;
Coutts, RT .
CELLULAR AND MOLECULAR NEUROBIOLOGY, 1997, 17 (02) :227-233
[7]   ON THE METABOLISM OF HALOPERIDOL [J].
GORROD, JW ;
FANG, J .
XENOBIOTICA, 1993, 23 (05) :495-508
[8]   CHARACTERIZATION OF DEXTROMETHORPHAN N-DEMETHYLATION BY HUMAN LIVER-MICROSOMES - CONTRIBUTION OF THE CYTOCHROME-P450 3A (CYP3A) SUBFAMILY [J].
GORSKI, JC ;
JONES, DR ;
WRIGHTON, SA ;
HALL, SD .
BIOCHEMICAL PHARMACOLOGY, 1994, 48 (01) :173-182
[9]   SUBSTANTIAL RISE IN SPARTEINE METABOLIC RATIO DURING HALOPERIDOL TREATMENT [J].
GRAM, LF ;
DEBRUYNE, D ;
CAILLARD, V ;
BOULENGER, JP ;
LACOTTE, J ;
MOULIN, M ;
ZARIFIAN, E .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 (02) :272-275
[10]  
GUENGERICH FP, 1989, ANNU REV PHARMACOL, V29, P241